Reta cancer data drops

Ok I'm posting the twitter link bc the wsj article is pay walled and it summarizes it.

View: https://x.com/agingroy/status/2057717218608099484?s=46&t=zVDa3_JfTajSPzmg_nqxMg


12,112 patients. Seven tumor types. GLP-1 users had half the lung cancer metastasis rate (10% vs 22%). Breast cancer: 43% cut. Colon cancer five-year mortality in a separate study: 15.5% vs 37.1%.

these effects are clearly beyond just weight loss, GLP agonists are showing more and more effects it's exciting stuff.
The GLP cancer paper has nothing to do with Reta. This study only includes currently on market GLP-agonists. This is not "Reta cancer data" since that data does not exist for a drug still in weight loss trials (Will Reta do the same? Probably, but there's no data yet).
 
I work in oncology and we did data analysis of over 400k cancer patients (of the GLP-1 users, 74% were prescribed GLP-1 after cancer diagnosis).

The correlations are pretty good. After 24 months, the OS (overall survival) rates for Breast and Prostate - 97.9% on GLP, 92.6% not on GLP.
 

Trending Topics

Forum Statistics

Threads
18,443
Posts
192,009
Members
61,735
Newest
Wakuja
Back
Top Bottom